Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models
Jason R. Clapper(Amplyx Pharmaceuticals (United States)), Jonathan D. Roth(Rutgers, The State University of New Jersey), Jennifer Athanacio(Amplyx Pharmaceuticals (United States)), P. S. Griffin, David G. Parkes(Amplyx Pharmaceuticals (United States)), Lawrence J. D’Souza, Carrie Wittmer(Amplyx Pharmaceuticals (United States))
Cited by 28
Related Papers
Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies
|Proceedings of the National Academy of Sciences|2008|433
Amylin: Pharmacology, Physiology, and Clinical Potential
|Pharmacological Reviews|2015|395
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism
|Nature Neuroscience|2010|348
Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2013|294
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2012|278